8-K: Molina Healthcare Reports Q4 Loss, Cuts 2026 Outlook

Molina Healthcare reported a fourth-quarter 2025 GAAP loss per diluted share of $3.15 and introduced lower full-year 2026 earnings guidance.

Summary

• Fourth quarter 2025 GAAP loss per diluted share was $3.15, and adjusted loss per diluted share was $2.75.
• Full year 2025 GAAP earnings per diluted share were $8.92, a 56% decrease year over year.
• Full year 2025 adjusted earnings per diluted share were $11.03, a 51% decrease year over year.
• Fourth quarter and full year 2025 results were burdened by approximately $2.00 per share from unfavorable retroactive Medicaid revenue adjustments in California and ongoing medical cost pressure in Medicare and Marketplace segments.
• Full year 2026 premium revenue guidance is approximately $42 billion, a decline of approximately 2% from full year 2025.
• Full year 2026 adjusted earnings guidance is at least $5.00 per diluted share.
• The 2026 adjusted earnings guidance is burdened by $2.50 per share, including $1.50 for the implementation of a new Florida Medicaid contract and $1.00 for underperformance in the traditional Medicare Advantage Part D (MAPD) product.
• The company will exit the traditional MAPD product for 2027, which has approximately $1 billion in annual premium.
• Operating cash flow for the full year 2025 was an outflow of $535 million, compared to an inflow of $644 million for the full year 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to significant Q4 losses, a substantial year-over-year decline in full-year earnings, and a much lower earnings guidance for 2026, driven by unfavorable adjustments and rising medical costs.

Positives

• Full year 2025 premium revenue increased 11% year over year to $43.1 billion, reflecting recent acquisitions, rate increases, and organic growth.
• The G&A ratio and adjusted G&A ratio for full year 2025 (6.6% and 6.5% respectively) reflect continued operating discipline and operating leverage.
• New store embedded earnings are now over $11.00 per diluted share, indicating future growth potential from newly awarded contracts and acquisitions.
• The company continues to produce positive pretax margins in Medicaid, even at what management believes is a low point in the industry cycle.

Negatives

• Fourth quarter 2025 GAAP loss per diluted share of $3.15 and adjusted loss per diluted share of $2.75.
• Full year 2025 GAAP earnings per diluted share decreased 56% year over year to $8.92, and adjusted earnings per diluted share decreased 51% year over year to $11.03.
• Results were burdened by approximately $2.00 per share of unfavorable retroactive premium adjustments attributable to California Medicaid and ongoing medical cost pressure in Medicare and Marketplace.
• The consolidated Medical Care Ratio (MCR) for full year 2025 increased to 91.7% from 89.1% in 2024, indicating higher medical costs relative to premiums.
• Medicaid MCR for full year 2025 was 91.8% due to continued high levels of utilization.
• Medicare MCR for full year 2025 was 92.4% due to higher utilization among high-acuity members and slower margin recovery in the Medicare Advantage Part D product.
• Marketplace MCR for full year 2025 was 90.6% due to much higher levels of utilization relative to risk adjustment revenue.
• Operating cash flow for the year ended December 31, 2025, was an outflow of $535 million, a significant decrease from an inflow of $644 million in 2024.
• The 2026 premium revenue guidance of approximately $42 billion represents a 2% decline from 2025.
• The 2026 adjusted earnings guidance of at least $5.00 per diluted share is substantially lower than the $11.03 reported for 2025.
• Parent company cash and investments decreased from $445 million as of December 31, 2024, to $223 million as of December 31, 2025.

Risks

• Unfavorable retroactive premium adjustments, particularly in the California Medicaid business, burdened 2025 results.
• Ongoing medical cost pressure due to continued high levels of utilization in Medicaid, Medicare, and Marketplace segments.
• Slower margin recovery in the Medicare Advantage Part D (MAPD) product, leading to the decision to exit this product for 2027.
• An imbalance between rates and trend marks 2026 as a 'trough year' for Medicaid industry margins, indicating sector-wide challenges.
• Implementation of new Medicaid contracts, such as the Florida CMS contract, can burden earnings in the initial phase.

Future Outlook

The company expects full year 2026 premium revenue of approximately $42 billion and adjusted earnings of at least $5.00 per diluted share. This guidance is significantly burdened by $2.50 per share due to the implementation of a new Florida Medicaid contract and underperformance in the traditional Medicare Advantage Part D (MAPD) product, which the company will exit for 2027. Management remains optimistic about the future earnings trajectory, anticipating rate restoration and future embedded earnings, with new store embedded earnings projected to be over $11.00 per diluted share between 2027 and 2029.

Management Comments

• "We remain confident in our durable and sustaining operating platform."
• "We believe that the imbalance between rates and trend marks 2026 as a trough year for Medicaid industry margins."
• "Even at this low point in the cycle, we continue to produce positive pretax margins in Medicaid."
• "We remain optimistic about the future earnings trajectory of the enterprise which includes anticipated rate restoration and future embedded earnings."

Industry Context

StockSavvy.ai notes that Molina Healthcare's challenges with Medicaid margins and high utilization reflect broader industry pressures in managed healthcare, particularly within government-sponsored programs. The company's expectation of 2026 as a 'trough year' for Medicaid industry margins suggests a sector-wide issue with the balance between reimbursement rates and medical cost trends. The decision to exit the traditional MAPD product for 2027 indicates a strategic shift towards more profitable or aligned segments, specifically the dual eligible business in Medicare, a trend seen in other large healthcare providers optimizing their portfolio amidst evolving regulatory and market dynamics.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or global benchmarks within the industry.

Legal Proceedings

• Non-recurring litigation costs were incurred for the year ended December 31, 2025, with no further details provided in this filing.

Stakeholder Impact

• Shareholders face negative impact due to significant earnings decline, a Q4 loss, and substantially reduced 2026 guidance, potentially leading to share price volatility.
• Customers (members) in the traditional Medicare Advantage Part D (MAPD) product will need to seek alternative coverage for 2027 as the company exits this segment.
• Government agencies (e.g., CMS, state Medicaid departments) are impacted by ongoing rate adjustments and contract implementations, such as the new Florida CMS Medicaid contract.

Next Steps

• Host a conference call and webcast on February 6, 2026, to discuss the fourth quarter and year-end 2025 results.
• File the Annual Report on Form 10-K for the year ended December 31, 2025, with the SEC.
• Exit the traditional Medicare Advantage Part D (MAPD) product for 2027 to focus on the dual eligible business in Medicare.
• Continue implementation of the new Florida CMS Medicaid contract.

Key Dates

Recommendation

The significant Q4 loss, substantial year-over-year decline in full-year 2025 earnings, and a drastically reduced 2026 earnings guidance, burdened by operational issues and unfavorable adjustments, indicate severe near-term headwinds. The negative operating cash flow and increased MCR further highlight deteriorating financial health. While there's a strategic shift and 'new store embedded earnings' potential, the immediate outlook is very challenging, suggesting a 'sell' recommendation for investors seeking to avoid further downside risk.

Keywords

Molina Healthcare, MOH, Q4 2025, Year-End 2025, 2026 Guidance, Financial Results, Earnings, Medicaid, Medicare, Marketplace, Medical Care Ratio, MCR, EPS, Healthcare Services, Managed Care, SEC Filing, 8-K